Over 2000 years ago in China, antibodies elicited by early forms of vaccination likely played a major role in the protection of the population from infectious agents. Vac- nation has been further developed in Europe and described by Edward Jenner in the late-eighteenth century, then successfully implemented worldwide. The idea to use theactiveingredientinthebloodofvaccinated(orimmunized)animalsorhumansfor the treatment of diseases came a century later. It was made possible by a series of discoveries,suchastherealizationthattheserumfromanimalsimmunizedwithtoxins, for example, diphtheria toxin or viruses, is an effective therapeutic against the disease causedbythesameagentinhumans. Inthe1880s,vonBehringdevelopedanantitoxin (anti-body) that did not kill the bacteria but neutralized the bacterial toxin. The first Nobel Prize in Medicine (1901) was given to him for the discovery of the serum therapy. Acenturylater,22monoclonalantibodies(mAbs)areapprovedbytheUnited States Food and Drug Administration (FDA) for clinical use, and hundreds are in clinicaltrialsforthetreatmentofvariousdiseasesincludingcancers,immunedisorders, and infections. The revenues from the top-five therapeutic antibodies reached $11. 7 billion in 2006, and major pharmaceutical companies raced to acquire antibody biotech companies with a recent example of MedImmune, Inc. , which was acquired for $15. 6 billion by AstraZeneca in 2007. This explosion of research and development in the field of therapeutic antibodies prompted the publication of the MiMB volume Therapeutic Antibodies: Methods and Protocols. The book's major goal is to present a set of protocols useful for researchers discoveringanddevelopingtherapeuticantibodies. Currentadvancesandfuturetrends in the antibody therapeutics are analyzed in thelead-in review article.
Rezensionen / Stimmen
From the reviews:
"This is an informative and practical handbook for those involved in the discovery and development of therapeutic antibodies. . Intended for those in the pharmaceutical industry or academia . and in the offices of those who direct projects which include this type of work. . This is a valuable addition to the libraries of those who perform day-to-day work in this field, or who manage projects involving therapeutic antibodies. . this is a valuable guide." (Frederick D. Coffman, Doody's Review Service, June, 2009)
Reihe
Auflage
Sprache
Verlagsort
Zielgruppe
Für Beruf und Forschung
Professional/practitioner
Illustrationen
Maße
Höhe: 266 mm
Breite: 198 mm
Dicke: 42 mm
Gewicht
ISBN-13
978-1-934115-92-3 (9781934115923)
DOI
10.1007/978-1-59745-554-1
Schweitzer Klassifikation
Recombinant Antigens.- Therapeutic Antibodies: Current State and Future Trends - Is a Paradigm Change Coming Soon?.- Preparation of Recombinant Viral Glycoproteins for Novel and Therapeutic Antibody Discovery.- Antibody Libraries.- Design of a Human Synthetic Combinatorial Library of Single-Chain Antibodies.- Construction of a Human Antibody Domain (VH) Library.- Generation and Selection of Rabbit Antibody Libraries by Phage Display.- Construction of a Large Naïve Human Phage-Displayed Fab Library Through One-Step Cloning.- Antibody Discovery.- Identification of Target and Function Specific Antibodies for Effective Drug Delivery.- Screening of Specific Internalization Fab Fragment from Human Naive Phage Library by Combinational Bio-Panning.- Competitive Antigen Panning for Selection of HIV-1 Neutralizing Human Monoclonal Antibodies Specific for gp41.- Selection of Non-aggregating VH Binders from Synthetic VH Phage-Display Libraries.- Isolation of Full-Length IgG Antibodies from Combinatorial Libraries Expressed in Escherichia coli.- Multiplexed Flow Cytometry: High-Throughput Screening of Single-Chain Antibodies.- Human Antibody Repertoires.- Rapid Screening Platform for Stabilization of scFvs in Escherichia coli.- Antibody Engineering.- In Vitro Antibody Affinity Maturation Targeting Germline Hotspots.- Affinity Maturation by Phage Display.- Production of Chimeric Heavy-Chain Antibodies.- Mammalian Cell Display for Antibody Engineering.- Improving Antibody Binding Affinity and Specificity for Therapeutic Development.- Construction and Production of an IgG-Like Tetravalent Bispecific Antibody for Enhanced Therapeutic Efficacy.- Deimmunization of Monoclonal Antibodies.- Anti-CD22 Onconase: Preparation and Characterization.- Antibody-Cytotoxic Agent Conjugates:Preparation and Characterization.- Antibody Preclinical Development.- High-Level Production of a Humanized ImmunoRNase Fusion Protein from Stably Transfected Myeloma Cells.- Antibody Fragment Expression and Purification.- Scaling-Up and Production of Therapeutic Antibodies for Preclinical Studies.- Antibody Production by the Gram-Positive Bacterium Bacillus megaterium.- Neutralization of HIV by Antibodies.- Dynamics of Antibody Domains Studied by Solution NMR.- In Vivo Method for Establishing Synergy Between Antibodies to Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2.- Passive Immunization with Human Neutralizing Monoclonal Antibodies Against HIV-1 in Macaque Models: Experimental Approaches.- Antibody Sequence Analysis.- Organizing, Exploring, and Analyzing Antibody Sequence Data: The Case for Relational-Database Managers.
